reset-myositis: an open-label study to evaluate the safety and efficacy of caba-201 in subjects with active idiopathic inflammatory myopathy or juvenile idiopathic inflammatory myopathy

Conditions: Idiopathic Inflammatory Myopathy; Dermatomyositis; Anti-Synthetase Syndrome; Immune-Mediated Necrotizing Myopathy; Juvenile Dermatomyositis; Juvenile Polymyositis; Juvenile Idiopathic Inflammatory Myopathy (JIIM); Juvenile Myositis

Summary: reset-myositis: open-label study to evaluate the safety and efficacy of caba-201 in subjects with active idiopathic inflammatory myopathy or juvenile idiopathic inflammatory myopathy

idiopathic inflammatory myopathies (iims, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. though the cause of iim is not well understood, some subtypes of iim, including dermatomyositis (dm), anti-synthetase syndrome (asys), immune-mediated necrotizing myopathy (imnm), and juvenile idiopathic inflammatory myopathy (jiim), are thought to involve b cells that cause the body to attack different tissues in the body. this study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, caba-201, that can be given to patients with dm, asys, imnm, or jiim who have active disease. a single dose of caba-201 in combination with cyclophosphamide (cy) and fludarabine (flu) will be evaluated.

Eligibility criteria:
adult cohorts inclusion criteria: * age ≥18 and ≤75 * a clinical diagnosis of iim, based on the 2017 the european league against rheumatism/american college of rheumatology classification criteria * diagnosis of dm, asys, imnm based on the presence of serum myositis-specific antibodies * evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (ck), dm rash, or active disease on muscle biopsy, magnetic resonance imaging (mri), or electromyography * presence of muscle weakness exclusion criteria: * contraindication to leukapheresis * history of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites * active infection requiring medical intervention at screening * current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. * concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures * significant lung or cardiac impairment * previous car t cell therapy * prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant juvenile cohort inclusion criteria: * age ≥6 and ≤17 years at enrollment * a clinical diagnosis of iim, based on the 2017 the european league against rheumatism/american college of rheumatology classification criteria * presence of serum myositis-specific antibodies or myositis-associated autoantibody * evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, dm rash, or active disease on muscle biopsy, magnetic resonance imaging (mri), or electromyography exclusion criteria: * contraindication to leukapheresis * history of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites * active infection requiring medical intervention at screening * current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. * concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures * significant lung or cardiac impairment * previous car t cell therapy * prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Keywords: caba-201 autoimmune disease anti-cd19 car-t therapy cellular therapy idiopathic inflammatory myopathy myositis dermatomyositis anti-synthetase syndrome immune-mediated necrotizing myopathy juvenile dermatomyositis juvenile polymyositis juvenile idiopathic inflammatory myopathy (jiim) juvenile myositis